

**FIG. 1**




FIG. 2A







FIG. 2B




*FIG. 2C*




*FIG. 2D*



**FIG. 3A**



**FIG. 3B**



**FIG. 3C**




FIG. 4B

FIG. 4C

(125-PRO) IL-2 (mM)

(125-PRO) IL-2 (mM)

IL-9 (u/ml)

FIG. 4A




FIG. 4F




FIG. 4E







FIG. 4D



**FIG. 5A**



**FIG. 5B**




IL-2R GAMMA CHAIN

IL-2R GAMMA CHAIN

**FIG. 5C**

INTERLEUKINE-2 RECEPTOR



**FIG. 6A**



IL-2 AND IP 130 SEQUENCE ( $\alpha$ -HELICES ARE BOXED)




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8A




FIG. 8B




FIG. 8C






FIG. 8D




- IL-4
- IL-4 + IP130

FIG. 9C




- IL-4
- IL-4 + IP130

FIG. 9B



- IL-4
- IL-4 + IP130

FIG. 9A




△ IP130 + mAb A41 (ANTI-IL-2R β)

■ IL-2 + mAb A41

□ IL-9 + mAb A41

FIG. 9D



△ IP130 + mAb A41 (ANTI-IL-2R β)


■ IL-2 + mAb A41

□ IL-9 + mAb A41

FIG. 9E


1	10	20	30		% HELIX (CIRCULAR DICHROISM)	MAIN MOLECULAR SPECIES	ACTIVITY
APTSSSTKKTKQLQEHLLDQLMLNGINN							
1	30				50% (150 @ 30 $\mu$ M) 35% (4 $\mu$ M)	TETRAMER (4M-8M, K <sub>d</sub> =30-100 $\mu$ M) /OCTAMER	+++
	10	30			22% (150 @ 30 $\mu$ M)	DIMER (1M-2M, K <sub>d</sub> =0.2 $\mu$ M) /TETRAMER (2M-4M, K <sub>d</sub> =100 $\mu$ M)	++
1	22				<2%		-
1	10				0%	DIMER (1M-2M, K <sub>d</sub> =50 $\mu$ M) (2M-4M, K <sub>d</sub> =1.4mM)	-
	5	15			0%	DIMER (1M-2M, K <sub>d</sub> =113 $\mu$ M)	-
	10	20			0%	MONOMER	ND
	20	20			<5%	MONOMER	+

FIG. 10



IP130

**FIG. 11A**



IP130

**FIG. 11B**






FIG.12A

# BLOT ANTI SHC





FIG. 12B

109020-1849460

NO STIMULATION  
IL - 2  
IP 130  
IL - 2 + IP 130



ACTIVATED STATs

FIG.13





FIG. 14

NK CELLS (CD56<sup>+</sup>) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION  
(SYNERGY WITH IL-2)


TREATMENT		J31	J32	J33
IL-2 50 nM		14	12	14
	IP130 60 $\mu$ M	0	17	$\leq 5$
	IP130 120 $\mu$ M	0	14	$< 5$
IL-2 50 nM + IP130	60 $\mu$ M	26	21	7
IL-2 50 nM + IP130	120 $\mu$ M	28	28	28

**FIG. 15**



EFFECTOR/TARGET = 10

*FIG. 16B*



EFFECTOR/TARGET = 10

*FIG. 16A*




FIG. 16C




FIG. 16D




FIG. 16F




FIG. 16E






FIGURE 17




FIGURE 18




FIGURE 19